What changed today in Aesthetics & Longevity: 1 trial update, 1 new study
Every new official record on the Aesthetics, Regenerative & Longevity Medicine desk since this morning, each linked to its primary source.
The signal
NPHLA tracked 2 new official records on this desk today: 1 trial update, 1 new study.
Why this matters
New clearances, safety communications and research in aesthetic and regenerative medicine affect what practices offer, how they describe it and what patients are told.
What changed
- Trial status changed to “Withdrawn”: SERCABOT (Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome)[1]
- New research in Biochimie: “Mesenchymal Stem Cells and Their Exosomes Modulate Sebocyte Fate and Lipid-Associated Proteomic-Lipidomic Remodeling”.[2]
- Also reported by STAT: “STAT+: Can you live longer for $5,500? Longevity clinics are the buzzy new trend at nonprofit hospitals”.[3]
Who this affects
- Med spas
- Medical directors
- Prescribers
- Practice owners & operators
- Pharmacies
What to watch next
No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.
NPHLA takeaway
These are factual summaries of official records with no interpretation. Open the primary documents for full details; NPHLA editors add analysis where developments warrant it.
Source file
- [1]
- [2]
- [3]
Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.
Update timeline
- First published.
- Added 1 new official record.